Document:

COLLATERAL AGENT AGREEMENT

          COLLATERAL AGENT AGREEMENT (this "Agreement") dated as of November ____, 2005, among Barbara R. Mittman (the "Collateral Agent"), and the parties identified on Schedule A hereto (each, individually, a "Lender" and collectively, the "Lenders"), who hold or will acquire convertible promissory notes issued or to be issued by Ceragenix Pharmaceuticals, Inc. ("Parent"), a Delaware corporation, at or about the date of this Agreement as described in the Security Agreement referred to in Section 1(a) below (collectively herein the "Notes").

          WHEREAS, the Lenders have made, are making and will be making loans to Parent to be secured by certain collateral; and

          WHEREAS, it is desirable to provide for the orderly administration of such collateral by requiring each Lender to appoint the Collateral Agent, and the Collateral Agent has agreed to accept such appointment and to receive, hold and deliver such collateral, all upon the terms and subject to the conditions hereinafter set forth; and

          WHEREAS, it is desirable to allocate the enforcement of certain rights of the Lenders under the Notes for the orderly administration thereof.

          NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, the parties hereto agree as follows:

          1.          Collateral.

                    (a)          Contemporaneously with the execution and delivery of this Agreement by the Collateral Agent and the Lenders, (i) the Collateral Agent has or will have entered into a Security Agreement among the Collateral Agent, Parent and Ceregenix Corporation, a Colorado corporation ("Guarantor" and together with Parent, "Debtors") ("Security Agreement"), regarding the grant of a security interest in assets owned by Debtors (such assets are referred to herein and in the Security Agreement as the "Collateral") to the Collateral Agent, for the benefit of the Lenders, (ii) Parent is issuing the Notes to the Lenders pursuant to a "Subscription Agreement" dated at or about the date of this Agreement. Collectively, the Security Agreement and may issue additional Notes pursuant to the Subscription Agreement, the Notes and Subscription Agreement and other agreements referred to therein are referred to herein as "Borrower Documents".

                    (b)          The Collateral Agent hereby acknowledges that any Collateral held by the Collateral Agent is held for the benefit of the Lenders in accordance with this Agreement and the Borrower Documents.  No reference to the Borrower Documents or any other instrument or document shall be deemed to incorporate any term or provision thereof into this Agreement unless expressly so provided.

                    (c)          The Collateral Agent is to distribute in accordance with the Borrower Documents any proceeds received from the Collateral which are distributable to the Lenders in proportion to their respective interests in the Obligations as defined in the Security Agreement.

          2.          Appointment of the Collateral Agent.

                    The Lenders hereby appoint the Collateral Agent (and the Collateral Agent hereby accepts such appointment) to take any action including, without limitation, the registration of any Collateral in the name of the Collateral Agent or its nominees prior to or during the continuance of an Event of Default (as defined in the Borrower Documents), the exercise of voting rights upon the occurrence and during the continuance of an Event of Default, the application of any cash collateral received by the Collateral Agent to the payment of the Obligations, the making of any demand under the Borrower Documents, the exercise of any remedies given to the Collateral Agent pursuant to the Borrower Documents and the exercise of any authority pursuant to the appointment of the Collateral Agent as an attorney-in-fact pursuant to the Security Agreement that the Collateral Agent deems necessary or proper for the administration of the Collateral pursuant to the Security Agreements.  Upon disposition of the Collateral in accordance with the Borrower Documents, the Collateral Agent shall promptly distribute any cash or Collateral in accordance with Section 10.4 of the Security Agreement.  Lenders must notify Collateral Agent in writing of the issuance of Notes to Lenders by Debtor.  The Collateral Agent will not be required to act hereunder in connection with Notes the issuance of which was not disclosed in writing to the Collateral Agent nor will the Collateral Agent be required to act on behalf of any assignee of Notes without the written consent of Collateral Agent.

          3.          Action by the Majority in Interest.

                    (a)          Certain Actions.  Each of the Lenders covenants and agrees that only a Majority in Interest shall have the right, but not the obligation, to undertake the following actions (it being expressly understood that less than a Majority in Interest hereby expressly waive the following rights that they may otherwise have under the Borrower Documents)

                              (i)          Acceleration.  If an Event of Default occurs, after the applicable cure period, if any, a Majority in Interest may, on behalf of all the Lenders, instruct the Collateral Agent to provide to Debtors notice to cure such default and/or declare the unpaid principal amount of the Notes to be due and payable, together with any and all accrued interest thereon and all costs payable pursuant to such Notes;

                              (ii)          Enforcement.  Upon the occurrence of any Event of Default after the applicable cure period, if any, a Majority in Interest may instruct the Collateral Agent to proceed to protect, exercise and enforce, on behalf of all the Lenders, their rights and remedies under the Borrower Documents against Debtors, and such other rights and remedies as are provided by law or equity;

                              (iii)          Waiver of Past Defaults.  A Majority in Interest may instruct the Collateral Agent to waive any Event of Default by written notice to Debtors, and the other Lenders; and

                              (iv)          Amendment.  A Majority in Interest may instruct the Collateral Agent to waive, amend, supplement or modify any term, condition or other provision in the Notes or Borrower Documents in accordance with the terms of the Notes or Borrower Documents so long as such waiver, amendment, supplement or modification is made with respect to all of the Notes and with the same force and effect with respect to each of the Lenders.

                    (b)          Permitted Subordination.  A Majority in Interest may instruct the Collateral Agent to agree to subordinate any Collateral to any claim and may enter into any agreement with Debtors to evidence such subordination; provided, however, that subsequent to any such subordination, each Note shall remain pari passu with the other Notes held by the Lenders.

                    (c)          Further Actions.  A Majority in Interest may instruct the Collateral Agent to take any action that it may take under this Agreement by instructing the Collateral Agent in writing to take such action on behalf of all the Lenders.

                    (d)          Majority in Interest.  For so long as any obligations remain outstanding on the Notes, Majority in Interest for the purposes of this Agreement and the Security Agreement shall mean Lenders who hold not less than sixty-five percent (65%) of the outstanding principal amount of the Notes.

          4.          Power of Attorney.

                    (a)          To effectuate the terms and provisions hereof, the Lenders hereby appoint the Collateral Agent as their attorney-in-fact (and the Collateral Agent hereby accepts such appointment) for the purpose of carrying out the provisions of this Agreement including, without limitation, taking any action on behalf of, or at the instruction of, the Majority in Interest at the written direction of the Majority in Interest and executing any consent authorized pursuant to this Agreement and taking any action and executing any instrument that the Collateral Agent may deem necessary or advisable (and lawful) to accomplish the purposes hereof.

                    (b)          All acts done under the foregoing authorization are hereby ratified and approved and neither the Collateral Agent nor any designee nor agent thereof shall be liable for any acts of commission or omission, for any error of judgment, for any mistake of fact or law except for acts of gross negligence or willful misconduct.

                    (c)          This power of attorney, being coupled with an interest, is irrevocable while this Agreement remains in effect.

          5.          Expenses of the Collateral Agent.  The Lenders shall pay any and all reasonable costs and expenses incurred by the Collateral Agent, including, without limitation, reasonable costs and expenses relating to all waivers, releases, discharges, satisfactions, modifications and amendments of this Agreement, the administration and holding of the Collateral, insurance expenses, and the enforcement, protection and adjudication of the parties' rights hereunder by the Collateral Agent, including, without limitation, the reasonable disbursements, expenses and fees of the attorneys the Collateral Agent may retain, if any, each of the foregoing in proportion to their holdings of the Notes.

          6.          Reliance on Documents and Experts.  The Collateral Agent shall be entitled to rely upon any notice, consent, certificate, affidavit, statement, paper, document, writing or communication (which may be by telegram, cable, telex, telecopier, or telephone) reasonably believed by it to be genuine and to have been signed, sent or made by the proper person or persons, and upon opinions and advice of its own legal counsel, independent public accountants and other experts selected by the Collateral Agent.

          7.          Duties of the Collateral Agent; Standard of Care.

                    (a)          The Collateral Agent's only duties are those expressly set forth in this Agreement, and the Collateral Agent hereby is authorized to perform those duties in accordance with commercially reasonable practices.  The Collateral Agent may exercise or otherwise enforce any of its rights, powers, privileges, remedies and interests under this Agreement and applicable law or perform any of its duties under this Agreement by or through its officers, employees, attorneys, or agents.

                    (b)          The Collateral Agent shall act in good faith and with that degree of care that an ordinarily prudent person in a like position would use under similar circumstances.

                    (c)          Any funds held by the Collateral Agent hereunder need not be segregated from other funds except to the extent required by law.  The Collateral Agent shall be under no liability for interest on any funds received by it hereunder.

          8.          Resignation.  The Collateral Agent may resign and be discharged of its duties hereunder at any time by giving written notice of such resignation to the other parties hereto, stating the date such resignation is to take effect.  Within five (5) days of the giving of such notice, a successor collateral agent shall be appointed by the Majority in Interest; provided, however, that if the Lenders are unable so to agree upon a successor within such time period, and notify the Collateral Agent during such period of the identity of the successor collateral agent, the successor collateral agent may be a person designated by the Collateral Agent, and any and all fees of such successor collateral agent shall be the joint and several obligation of the Lenders.  The Collateral Agent shall continue to serve until the effective date of the resignation or until its successor accepts the appointment and receives the Collateral held by the Collateral Agent but shall not be obligated to take any action hereunder.  The Collateral Agent may deposit any Collateral with the Supreme Court of the State of New York for New York County or any such other court in New York State that accepts such Collateral.

          9.          Exculpation.  The Collateral Agent and its officers, employees, attorneys and agents, shall not incur any liability whatsoever for the holding or delivery of documents or the taking of any other action in accordance with the terms and provisions of this Agreement, for any mistake or error in judgment, for compliance with any applicable law or any attachment, order or other directive of any court or other authority (irrespective of any conflicting term or provision of this Agreement), or for any act or omission of any other person engaged by the Collateral Agent in connection with this Agreement, unless occasioned by the exculpated person's own gross negligence or willful misconduct; and each party hereto hereby waives any and all claims and actions whatsoever against the Collateral Agent and its officers, employees, attorneys and agents, arising out of or related directly or indirectly to any or all of the foregoing acts, omissions and circumstances. 

          10.          Indemnification.  The Lenders hereby agree to indemnify, reimburse and hold harmless the Collateral Agent and its directors, officers, employees, attorneys and agents, jointly and severally, from and against any and all claims, liabilities, losses and expenses that may be imposed upon, incurred by, or asserted against any of them, arising out of or related directly or indirectly to this Agreement or the Collateral, except such as are occasioned by the indemnified person's own gross negligence or willful misconduct.

          11.          Miscellaneous.

                    (a)          Rights and Remedies Not Waived.  No act, omission or delay by the Collateral Agent shall constitute a waiver of the Collateral Agent's rights and remedies hereunder or otherwise.  No single or partial waiver by the Collateral Agent of any default hereunder or right or remedy that it may have shall operate as a waiver of any other default, right or remedy or of the same default, right or remedy on a future occasion.

                    (b)          Governing Law.  This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York
without regard to conflicts of laws that would result in the application of the substantive laws of another jurisdiction.

                    (c)          Waiver of Jury Trial and Setoff; Consent to Jurisdiction; Etc.

                              (i)          In any litigation in any court with respect to, in connection with, or arising out of this Agreement or any instrument or document delivered pursuant to this Agreement, or the validity, protection, interpretation, collection or enforcement hereof or thereof, or any other claim or dispute howsoever arising, between the Collateral Agent and the Lenders or any Lender, then each Lender, to the fullest extent it may legally do so, (A) waives the right to interpose any setoff, recoupment, counterclaim or cross-claim in connection with any such litigation, irrespective of the nature of such setoff, recoupment, counterclaim or cross-claim, unless such setoff, recoupment, counterclaim or cross-claim could not, by reason of any applicable federal or state procedural laws, be interposed, pleaded or alleged in any other action; and (B)
WAIVES TRIAL BY JURY IN CONNECTION WITH ANY SUCH LITIGATION AND ANY RIGHT IT MAY HAVE TO CLAIM OR RECOVER IN ANY SUCH LITIGATION ANY SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES OR ANY DAMAGES OTHER THAN, OR IN ADDITION TO, ACTUAL DAMAGES.  EACH LENDER AGREES THAT THIS SECTION 11(c) IS A SPECIFIC AND MATERIAL ASPECT OF THIS AGREEMENT AND ACKNOWLEDGE THAT THE COLLATERAL AGENT WOULD NOT ENTER THIS AGREEMENT IF THIS SECTION 11(c) WERE NOT PART OF THIS AGREEMENT.

                              (ii)          Each Lender irrevocably consents to the exclusive jurisdiction of any State or Federal Court located within the County of New York, State of New York, in connection with any action or proceeding arising out of or relating to this Agreement or any document or instrument delivered pursuant to this Agreement or otherwise.  In any such litigation, each Lender waives, to the fullest extent it may effectively do so, personal service of any summons, complaint or other process and agree that the service thereof may be made by certified or registered mail directed to such Lender at its address for notice determined in accordance with Section 11(e) hereof.  Each Lender hereby waives, to the fullest extent it may effectively do so, the defenses of forum non conveniens and improper venue.

                    (d)          Admissibility of this Agreement.  Each of the Lenders agrees that any copy of this Agreement signed by it and transmitted by telecopier for delivery to the Collateral Agent shall be admissible in evidence as the original itself in any judicial or administrative proceeding, whether or not the original is in existence.

                    (e)          Address for Notices. Any notice or other communication under the provisions of this Agreement shall be given in writing and delivered in person, by reputable overnight courier or delivery service, by facsimile machine (receipt confirmed) with a copy sent by first class mail on the date of transmissions, or by registered or certified mail, return receipt requested, directed to such party's addresses set forth below (or to any new address of which any party hereto shall have informed the others by the giving of notice in the manner provided herein):

                    In the case of the Collateral Agent, to her at:

                    Barbara R. Mittman, Esq.

                    Grushko & Mittman, P.C.

                    551 Fifth Avenue, Suite 1601

                    New York, NY 10176

                    Fax: (212) 697-3575

                    With a copy to:

                    Grushko & Mittman, P.C.

                    551 Fifth Avenue, Suite 1601

                    New York, New York 10176

                    Fax: (212) 697-3575

                    In the case of the Lenders, to:

                    To the address and telecopier number set forth on
Schedule A hereto.

                    In the case of Debtors, to:

                    Ceragenix Pharmaceuticals, Inc.

                    1444 Wazee Street, Suite 210

                    Denver, CO 80202

                    Attn: Steven S. Porter, CEO

                    Fax: (303) 534-1860

                    With a copy by telecopier only to:

                    Cliff Neuman, Esq.

                    Clifford L. Neuman, P.C.

                    Temple-Bowron House

                    1507 Pine Street

                    Boulder, CO 80302

                    Fax: (303) 449-1045

                    (f)          Amendments and Modification; Additional Lender.  No provision hereof shall be modified, altered, waived or limited except by written instrument expressly referring to this Agreement and to such provision, and executed by the parties hereto.  Any transferee of a Note who acquires a Note after the date hereof will become a party hereto by signing the signature page and sending an executed copy of this Agreement to the Collateral Agent and receiving a signed acknowledgement from the Collateral Agent.

                    (g)          Fee.  Upon the occurrence of an Event of Default, the Lenders collectively shall pay the Collateral Agent the sum of $10,000 to apply against an hourly fee of $350 to be paid to the Collateral Agent by the Lenders for services rendered pursuant to this Agreement.  All payments due to the Collateral Agent under this Agreement including reimbursements must be paid when billed.  The Collateral Agent may refuse to act on behalf of or make a distribution to any Lender who is not current in payments to the Collateral Agent.  Payments required pursuant to this Agreement shall be pari passu to the Lenders' interests in the Notes.  The Collateral Agent is hereby authorized to deduct any sums due the Collateral Agent from Collateral in the Collateral Agent's possession.

                    (h)           Counterparts/Execution.  This Agreement may be executed in any number of counterparts and by the different signatories hereto on separate counterparts, each of which, when so executed, shall be deemed an original, but all such counterparts shall constitute but one and the same instrument.  This Agreement may be executed by facsimile signature and delivered by facsimile transmission.

                    (i)          Successors and Assigns.  Whenever in this Agreement reference is made to any party, such reference shall be deemed to include the successors, assigns, heirs and legal representatives of such party.  No party hereto may transfer any rights under this Agreement, unless the transferee agrees to be bound by, and comply with all of the terms and provisions of this Agreement, as if an original signatory hereto on the date hereof.

                    (j)          Captions: Certain Definitions.  The captions of the various sections and paragraphs of this Agreement have been inserted only for the purposes of convenience; such captions are not a part of this Agreement and shall not be deemed in any manner to modify, explain, enlarge or restrict any of the provisions of this Agreement.  As used in this Agreement the term "person" shall mean and include an individual, a partnership, a joint venture, a corporation, a limited liability company, a trust, an unincorporated organization and a government or any department or agency thereof.

                    (k)          Severability.  In the event that any term or provision of this Agreement shall be finally determined to be superseded, invalid, illegal or otherwise unenforceable pursuant to applicable law by an authority having jurisdiction and venue, that determination shall not impair or otherwise affect the validity, legality or enforceability (i) by or before that authority of the remaining terms and provisions of this Agreement, which shall be enforced as if the unenforceable term or provision were deleted, or (ii) by or before any other authority of any of the terms and provisions of this Agreement.

                    (l)          Entire Agreement.  This Agreement contains the entire agreement of the parties and supersedes all other agreements and understandings, oral or written, with respect to the matters contained herein.

                    (m)          Schedules.  The Collateral Agent is authorized to annex hereto any schedules referred to herein.

[THIS SPACE INTENTIONALLY LEFT BLANK]

          IN WITNESS WHEREOF, the parties hereto have caused this Collateral Agent Agreement to be signed, by their respective duly authorized officers or directly, as of the date first written above.

	
"LENDERS":

	 	 
	
______________________________________
	
_______________________________________

	
LONGVIEW EQUITY FUND, L.P.
	
LONGVIEW FUND, L.P.

	
_______________________________________
	
_______________________________________

	
ALPHA CAPITAL AKTIENGESELLSCHAFT
	
IROQUOIS CAPITAL

	 	 
	 	
_______________________________________

	 	
BARBARA R. MITTMAN - Collateral Agent

Acknowledged:

CERAGENIX PHARMACEUTICALS, INC.

By:__________________________________

Name:

Title:

This Collateral Agent Agreement may be signed by facsimile signature and delivered by confirmed facsimile transmission.

 

SCHEDULE A TO COLLATERAL AGENT AGREEMENT 

	
LENDER
	
PURCHASE PRICE

	
LONGVIEW EQUITY FUND, LP

600 Montgomery Street, 44th Floor

San Francisco, CA 94111

Fax: (415) 981-5301
	
$500,000.00

	
LONGVIEW FUND, LP

600 Montgomery Street, 44th Floor

San Francisco, CA 94111

Fax: (415) 981-5301
	
$2,000,000.00

	
ALPHA CAPITAL AKTIENGESELLSCHAFT

Pradafant 7

9490 Furstentums

Vaduz, Lichtenstein

Fax: 011-42-32323196
	
$500,000.00

	
IROQUOIS CAPITAL

641 Lexington Avenue, 26th Floor

New York, NY 10022

Fax: (212) 207-1412
	
$200,000.00

	
TOTAL
	
$3,200,000.00<PAGE>

                                                                    Exhibit 10.1

                               INVESTMENT CONTRACT
                               -------------------
                  ACCREDITED INVESTORS ONLY: MAIE STATES AND CA

                                   A. PARTIES

         This agreement is entered into this ____ day of _____________, 2005, by
and between INGEN TECHNOLOGIES, INC., a Georgia corporation and
__________________, a resident or entity of ________________ ("subscriber").

                             B. RECITALS AND SUMMARY

         Ingen Technologies, Inc. ("COMPANY") intends to raise up to $1 million
utilizing Rule 504 of Regulation D of the SEC in states that have adopted (at
least in substantial form) the Model Accredited Investor Exemption ("MAIE"),
plus California - under Corp. Code section 25102(n). Common shares purchased
hereunder will be unrestricted shares. Management has no current plans to pay
commissions or finders fees, but is not prohibited from so doing.

         The COMPANY is a "development stage enterprise" with no significant
operating history and no sales of its products to date. Mr. Scott R. Sand is CEO
and Chairman of the COMPANY and should be contacted by prospective investors
desiring more information concerning this investment opportunity.

         The COMPANY is competing in the electronic medical monitoring device
industry against competitors with superior track records and resources. This is
a HIGH RISK INVESTMENT that should be undertaken only by accredited,
sophisticated people with the means to risk loss of the entire investment.

         Those persons or entities domiciled in the following states are
eligible to participate in this AGREEMENT: Alaska, Arizona, California,
Colorado, Connecticut, Delaware, District of Columbia, Indiana, Kansas,
Kentucky, Maine, Maryland, Nevada, New Jersey, New Mexico, North Dakota,
Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah,
Vermont, Virginia, Washington, West Virginia, Wisconsin.

         The amount of investment in this AGREEMENT is $_______________, for the
purchase of __________________ shares of unrestricted COMPANY common shares (to
be issued by the COMPANY'S Transfer Agent ASAP upon receipt of funds). Payment
must be received within five business days of the date first written above.

                         C. OTHER TERMS OF THE CONTRACT

         This offering is limited to qualified persons and entities who are
accredited as defined by federal law (Regulation D of the Securities and
Exchange Commission). Subscribers must have the experience, knowledge and
sophistication to ascertain the suitability of this investment opportunity in
relation to their own needs and/or have a pre-existing personal, family or
business relationship with management and/or its officials.

                                      -1-
<PAGE>

         There is no impound amount in this offering. All proceeds from this
stock offer and purchase hereunder will go directly into the COMPANY's bank
account to be utilized as contained below. Prospective investors should realize
that additional investment may be required before the COMPANY is able to begin
the manufacture and sale of its proprietary products. There is no guarantee the
COMPANY will be able to raise enough funds in this or some other offering
enabling it to progress beyond its current developmental stage of operation.

                       D. COMPLIANCE WITH SECURITIES LAWS

         The parties understand that this Agreement is in the nature of a
"security" as defined under applicable state and federal law. This is primarily
because the investment provided for herein is in the nature of a "passive
investment" wherein subscriber is providing funds for the COMPANY through
purchase of common stock, but not participating in the active management of the
funds.

         It is understood that this Agreement will not be registered with any
state or federal securities regulatory authority and that the parties are
relying upon exemptions from registration under state and federal law, or, the
parties are relying on a federal law "private placement" exemption that
pre-empts state law. No state or federal securities regulator has read or passed
upon the merits or adequacy of this Agreement.

                          E. ESTIMATED USE OF PROCEEDS

          Funds will be utilized for engineering, tooling, marketing and
inventory production of the COMPANY's product OxyAlert and for general and
administrative expenses. Management should be contacted directly for more
specific information regarding OxyAlert and the COMPANY's operation.

                     F. ALLOCATIONS AND PROFIT PARTICIPATION

         The COMPANY has no current dividend policy in place. The COMPANY is a
development stage COMPANY and there are no plans to pay shareholder dividends
until and if the COMPANY progresses to the point of generating sales revenues
beyond that needed to operate and grow the COMPANY.

                                  G. MANAGEMENT

         The resume of Mr. Sand is attached hereto. Other officers and directors
of the COMPANY (as well as additional information about the COMPANY and its
business) can be found on the COMPANY's website: www.Ingen-Tech.com.

                 H. COMPENSATION, STOCK OWNERSHIP OF MANAGEMENT

         Management is compensated as follows:

         (include name, position, monthly salary or fee)

         Management owns stock in the COMPANY as follows:

         (include name, position, number of shares owned and optioned)

                                      -2-
<PAGE>

                     I. SALE OF COMPANY STOCK BY MANAGEMENT

         Management will market the unrestricted common stock offered hereby.
Management will not pay itself commissions regarding these sales. Management has
no current plans to pay commissions or finders fees to third parties regarding
the sale of stock herein, but reserves the right to pay such reasonable
compensation if necessary (in the sound discretion of Management). The payment
of any compensation for sale of the COMPANY's securities will reduce the amount
of proceeds available for the uses as mentioned above.

                J. REPRESENTATIONS AND WARRANTIES OF THE COMPANY

          The COMPANY represents and warrants that it is properly formed and in
good standing in the state of Georgia. The COMPANY represents and warrants that
Management will use its best efforts to raise or otherwise provide enough
funding to move the COMPANY out of its developmental stage. Management will
conduct all business on behalf of the COMPANY in a professional and timely
manner. The COMPANY represents and warrants that it has the legal right to
develop, manufacture and sell its products.

       K. REPRESENTATIONS AND WARRANTIES OF SUBSCRIBER ("THE UNDERSIGNED")

         1. The undersigned has received and carefully reviewed, and is familiar
with this Agreement and all material incorporated by reference herein, all
amendments and attachments delivered herewith. In evaluating the suitability of
an investment in this Agreement, the undersigned has not relied upon any
representations or other information (whether oral or written) from the COMPANY,
its officers, directors, managers or employees other than as set forth in the
Agreement and other delivered materials.

         2. The undersigned has such knowledge and experience in financial and
business matters that he/she is capable of evaluating the merits and risks of
the prospective entrance into this Agreement.

         3. The undersigned has obtained, to the extent he/she deems necessary,
his/her own personal professional advice with respect to the risks inherent in
the investment in this Agreement, and the suitability of the investment in light
of his/her financial condition and investment needs.

         4. The undersigned believes that the investment in this Agreement is
suitable for him/her based upon his/her investment objectives and financial
needs, and the undersigned is accredited and has adequate means of providing for
his/her current financial needs and personal contingencies and has no need for
liquidity of investment with respect to this Agreement.

         5. The undersigned has been given access to full and complete
information regarding the COMPANY, its Management and business plan, and has
utilized such access to his/her/its satisfaction, or waived the opportunity to
do so, for the purpose of asking questions and receiving answers concerning the
terms and conditions of this Agreement, obtaining information in addition to, or
verifying information included in, this Agreement, and obtaining any of the
documents or information described herein. The undersigned has either attended
or been give reasonable opportunity to attend a meeting with representatives of
the COMPANY for the purpose of asking questions of, and receiving answers from,
such representatives concerning the terms and conditions of this Agreement and
to obtain any additional information, to the extent reasonably available,
necessary to verify the accuracy of information provided in this Agreement.

                                      -3-
<PAGE>

         6. The undersigned recognizes that the COMPANY has a limited operating
history, and that entry into this Agreement as an investment involves a high
degree of risk including, but not limited to, the risk of economic losses from
operations of the COMPANY and the risks involved in developing, producing,
marketing an electronic medical monitoring device.

         7. The undersigned realizes that although he/she/it is receiving
unrestricted common COMPANY shares, that there is no public market for the
shares and no guarantee that the there will ever be a public market for the
shares. The price of the shares has been arbitrarily established by Management
without regard to the financial condition of the COMPANY.

         8. The undersigned acknowledges that the COMPANY and its affiliates
have not retained counsel to provide its prospective investors with
representation in connection with this offering. The undersigned also
acknowledges that he/she/it understands that (i) no counsel has undertaken any
independent due diligence investigation of the facts and circumstances relating
to this offering, and (ii) he/she/it must assume responsibility for his/her/its
own due diligence investigation, and (iii) the protection afforded by a complete
due diligence investigation of counsel is not present in this offering.

         9. The undersigned acknowledges that he/she/it understands the risk
that insufficient capital will be raised in this offering or in any subsequent
offering or financing to assist in accomplishing the COMPANY's goals; and that
there is absolutely no assurance that (a) the COMPANY will complete this private
offering of its stock; (b) that the COMPANY will be able to operate profitably.
Further, the undersigned acknowledges that if the COMPANY is unable to
successfully conclude this offering, any other private offering or obtain other
financing, the COMPANY (and, therefore, the undersigned) would suffer a
substantial loss which may result in the COMPANY not being able to develop and
market the COMPANY's product or product line.

         10. The undersigned has been advised that this Agreement has not being
registered under the Act or the relevant state securities law, but are being
offered and sold pursuant to exemptions from such registrations, and that the
COMPANY's reliance upon such exemptions is predicated partly on the
undersigned's representations to the COMPANY as contained herein.

         11. The undersigned represents and warrants that he/she/it is a bona
fide resident of, and is domiciled in, the State of ________________ (one of the
states listed as a MAIE state herein, or California), and that his/her/its entry
into this Agreement by him/he/it in his/her/its name solely for his/her/its own
beneficial interest and not as nominee for, or on behalf of, or for the
beneficial interest of, or with the intention to transfer to, any other person,
trust, or organization.

         12. The undersigned is informed of the significance to the COMPANY of
the foregoing representations, and such representations are made with the
intention that the COMPANY will rely on the same. The undersigned shall
indemnify and hold harmless the COMPANY, its officers, directors, managers and
agents against any losses, claims, damages, or liabilities to which they, or any
of them, may become subject insofar as such losses, claim, damages, or
liabilities (or actions in respect thereof) arise from any misrepresentation or
misstatement of facts or omission to represent or state facts made by the
undersigned to the COMPANY concerning the undersigned or the undersigned's
financial position in connection with the offering or sale of the Securities.

                                      -4-
<PAGE>

         13. The undersigned, if other than an individual, makes the following
additional representations and warranties:

                  a. The undersigned was not organized for the specific purpose
of entering into this Agreement.

                  b. The execution of this Agreement has been duly authorized by
all necessary action on the part of the undersigned, has been duly executed by
the authorized officer or representative of the undersigned, and is a legal,
valid and binding obligation of the undersigned enforceable in accordance with
its terms.

         14. The undersigned, if executing this Agreement in a representative or
fiduciary capacity, (ii) represents that he/she/it has full power and authority
to execute and deliver this Agreement on behalf of the subscribing individual,
partnership, trust, estate, corporation, or other entity for whom the
undersigned is executing this Agreement, and such individual, partnership,
trust, estate, corporation, or other entity has full right and power to perform
pursuant to such Agreement and become a shareholder of the COMPANY and (ii)
acknowledges that the representations and warranties contained herein shall be
deemed to have been made on behalf of the person or persons for whom the
undersigned is so purchasing.

         15. If applicable, the undersigned represents that if he/she/it is a
"non-U.S. person" (residing outside of the United States) and that he/she/it
will hold the securities for a period of at least one year before selling or
otherwise transferring the securities to a "U.S. person" (residing within the
United States) as required by Regulation S of the United State Securities and
Exchange Commission.

         16. Confidentiality.

                  a. The provisions of this Agreement are confidential and
private and are not to be disclosed to outside parties (except on a reasonable
need to know basis only) without the written and express, advance consent of all
parties hereto.

                  b. Subscriber agrees and acknowledges that in his/her/its
association with the COMPANY under this Agreement, he/she/it may come into
possession or knowledge of confidential and/or proprietary information. Such
confidential and/or proprietary information includes, but is not limited to:
information regarding agents, contractors, employees and all affiliates of which
the COMPANY possesses an ownership interest of ten percent (10%) or greater;
corporate and/or financial information and records of or any client, customer or
associate of the COMPANY; customer information; client information; shareholder
information; business contacts; investor leads and contacts; employee
information; documents regarding the COMPANY's website and any product, business
plan or presentation materials of the COMPANY.

         Subscriber represents and warrants to the COMPANY that he, she or it
will not divulge confidential, proprietary information of the COMPANY or any of
its subsidiaries to anyone or anything without the written and express, advance
consent of the COMPANY, and further represents and warrants that he, she or it
will not use any proprietary information of the COMPANY for his or her or its or
anyone else's gain or advantage at any time during or after the Term of this
Agreement.

                                      -5-
<PAGE>

                             L. PRODUCT INFORMATION

         Information concerning the COMPANY'S products maybe obtained online at
the COMPANY'S website as mentioned above, or by contacting Management.

                           M. REPORTS TO SHAREHOLDERS

         Shareholders will receive annual reports from Management containing
pertinent COMPANY business information. Shareholders, under law, have a right of
inspection of the books of the COMPANY for certain limited purposes.

                          N. LITIGATION, LEGAL MATTERS

         Management has no information leading it to believe that litigation is
imminent or planned by anyone with respect to the COMPANY.

                            O. ACCESS TO INFORMATION

         Prospective shareholders have the right to request additional
information relative to this private placement of securities and Management, to
the extent it can reasonably and affordably supply the same, has the duty to
supply the same in a timely manner.

                      P. MISCELLANEOUS LEGAL CONSIDERATIONS

         1. Modifications and Amendments. The terms and conditions of this
Agreement may be amended at any time and from time to time, in whole and in
part, upon written agreement signed by a duly authorized officer of the COMPANY
and subscriber.

         2. Expenses. Each party shall bear its own respective costs, fees and
expenses associated with entering into and executing its duties under this
Agreement.

         3. Indemnification. Each party, if an offending party, agrees to
indemnify and hold harmless all other parties from any claim of damage of any
party or non-party arising out of any act or omission of the offending party
arising from this Agreement.

         4. Notices. Any notice, request, proposal, statement or other
communication required or permitted to be given hereunder shall be in writing
and shall be deemed given when personally delivered or confirmed by facsimile or
ten (10) days after mailed by certified mail, postage prepaid, to the parties at
their respective addresses first set forth above or to such other address of
which a party shall have theretofore notified the other by a notice given in
accordance with this Paragraph, together with a courtesy copy to the receiving
party's counsel, as follows:

If to the COMPANY:
-----------------
Ingen Technologies, Inc.
285 E. County Line Rd.
Calimesa, CA 92320

                                      -6-
<PAGE>

If to Subscriber:
-----------------

         5. Breach. In the event of a breach of this Agreement, the breaching
party shall be notified by the other party by written notice pursuant to the
Notices Paragraph herein within ten (10) days of reasonable discovery of the
breach. Upon notice so given, the breach shall be corrected within fifteen (15)
days. If the breach is not corrected within this period, the non-breaching party
may take appropriate legal action consistent with the terms of this Agreement.

         6. Assignment. The provisions of this Agreement shall be binding upon
and inure to the benefit of the COMPANY and Subscriber and their respective
successors, assigns and personal representatives. If the COMPANY shall at any
time be merged or consolidated into or with any other corporation or if the
COMPANY's stock or substantially all of its assets are transferred to another
corporation, the provisions of this Agreement shall be binding upon and inure to
the benefit of Subscriber and the corporation resulting from such merger or
consolidation or to which such capital stock or assets shall be transferred, and
this provision shall apply in the event of any subsequent merger, consolidation
or transfer.

         7. Entire Agreement. This Agreement is the full and complete,
integrated agreement of the parties, merging and superseding all previous
written and/or oral agreements and representations between the parties, and is
amendable only as provided for herein.

         8. Governing Law. This Agreement shall be governed by the laws of the
State of California applicable to contracts made to be performed entirely
therein, and each party agrees to submit to the personal jurisdiction of any
Court of competent jurisdiction in _________________ County and to all the rules
and orders of such Court, and the laws of the State of California.

         9. Waiver. Any waiver by either party of any provision of this
Agreement or any right hereunder shall not be deemed a continuing waiver and
shall not prevent or estop such party from thereafter enforcing such provision,
and the failure of either party to insist in any one or more instances upon the
strict performance of any of the provisions of this Agreement by the other party
shall not be construed as a waiver or relinquishment for the future performance
of any such term or provision, but the same shall continue in full force and
effect.

         10. Enforcement. If the parties cannot settle any dispute arising out
of or relating to this Agreement, or the breach thereof, in a reasonable and
timely fashion, either party may file for binding arbitration (as the exclusive
means of dispute resolution) within ___________________ County, California.
Arbitration shall be governed by the rules of the American Arbitration
Association and judgment upon the award may be entered in any Court having
jurisdiction thereof. The arbitrator(s) may award reasonable attorneys fees and
costs to the prevailing party. However, the parties agree to reserve the right
to obtain a preliminary injunction from a court of competent jurisdiction if
necessary in the event of a material breach arising from this Agreement.

                                      -7-
<PAGE>

         11. Headings. The headings in this Agreement are solely for convenience
of reference and shall not affect its interpretation.

         12. Possible Invalidity. In case any provision of this Agreement should
be held to be contrary to, or invalid under, the law of any country, state or
other jurisdiction, such illegality or invalidity shall not affect in any way
any of the other provisions hereof, this Agreement in such event to be construed
as though the offending provision had been deleted or modified in such a manner
as to make it enforceable to the maximum extent possible to reflect the parties'
intent hereunder, and all of the provisions hereof nevertheless shall continue
unmodified and in full force and effect in any country, state or jurisdiction in
which such provisions are legal and valid.

         13. Counterparts. This Agreement may be executed in counterparts, each
of which shall be deemed an original and all of which together shall constitute
one and the same agreement. Facsimile signatures shall be considered as valid
and binding as original signatures.

         14. Independent Covenants: Each of the respective rights and
obligations of the parties hereunder shall be deemed independent and may be
enforced independently irrespective of any of the other rights and obligations
set forth herein.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date
first written above.

-------------------------------------      -------------------------------------
INGEN TECHNOLOGIES, INC.                   SUBSCRIBER
By:  Scott R. Sand, CEO & Chairman

                                      -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}]]